Quick Answer
Glucotrack, Inc. reported R&D Expense of $9.81 million for fiscal year 2025.
Glucotrack, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $9.81M | +3.3% |
| 2024 | $9.50M | +101.9% |
| 2023 | $4.70M | +139.1% |
| 2022 | $1.97M | +8.7% |
| 2021 | $1.81M | +18.1% |
| 2020 | $1.53M | -4.6% |
| 2019 | $1.61M | -47.0% |
| 2018 | $3.03M | -5.4% |
| 2017 | $3.21M | +11.3% |
| 2016 | $2.88M | +27.0% |
| 2015 | $2.27M | +22.6% |
| 2014 | $1.85M | -6.9% |
| 2013 | $1.99M | +3.4% |
| 2012 | $1.92M | +7.3% |
| 2011 | $1.79M | +91.6% |
| 2010 | $934.1K | -7.1% |
| 2009 | $1.01M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $3.17M | +53.4% | +0.5% |
| June 30, 2025 | $3.15M | -12.2% | +68.4% |
| March 31, 2025 | $1.87M | -12.9% | -9.3% |
| September 30, 2024 | $2.06M | +21.9% | -42.5% |
| June 30, 2024 | $3.59M | +472.4% | +67.1% |
| March 31, 2024 | $2.15M | +234.6% | +26.9% |
| September 30, 2023 | $1.69M | +290.1% | +170.0% |
| June 30, 2023 | $627.0K | +33.7% | -2.3% |
- Glucotrack, Inc. showed an increase of +3.3% in R&D Expense compared to the prior fiscal year.
- Over the 2009–2025 period, Glucotrack, Inc.’s r&d expense has grown by 876.3% (from $1.01 million to $9.81 million).
- The most recent figure is from Glucotrack, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: